Eric Lefkofsky on AI adoption
From Tempus AI Investor Day 2026 | Precision Medicine Diagnostic Data Library Sells Fuel Growth Plans · · Investing 101
“If the question is whether or not data and AI and technology are going to permeate drug discovery and development and healthcare, the answer is like 100% yes. It can't not happen. Every industry who ever has said it's not going to happen has been washed away by technology.”
On , Eric Lefkofsky, Cofounder at Tempus, spoke about AI adoption during Tempus AI Investor Day 2026 | Precision Medicine Diagnostic Data Library Sells Fuel Growth Plans on Investing 101.
About Eric Lefkofsky
At Tempus AI’s 2026 Investor Day, Eric Lefkofsky described the company’s founding mission as using artificial intelligence to unlock precision medicine. He stated that Tempus has built a “connected ecosystem” that generates data from clinical workflows, turns that data into insights, and feeds those insights back into the healthcare system, which he called “sustainable.” Lefkofsky said the company’s data and modeling tools are used across the drug R&D lifecycle, from early-stage discovery through commercialization, and that Tempus licenses multimodal data to biopharma customers. Lefkofsky expressed confidence that data, AI, and technology will “permeate drug discovery and development and healthcare,” adding that “every industry who ever has said it’s not going to happen has been washed away by technology.” He predicted that real-world data insights will eventually be layered onto every therapeutically relevant biomarker. He also speculated that “there will come a time when no phase 3s ever fail,” attributing failures to either a misunderstood mechanism of action or a mismatch between phase 2 and phase 3 results.